• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Moderna Set to Join S&P 500

    7/15/21 7:01:00 PM ET
    $SPGI
    $ALXN
    $AZN
    $MRNA
    Finance: Consumer Services
    Finance
    Major Pharmaceuticals
    Health Care
    Get the next $SPGI alert in real time by email

    NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 21, 2021

    S&P 500

    Addition

    Moderna

    MRNA

    Health Care



    S&P 500

    Deletion

    Alexion Pharmaceuticals

    ALXN

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/moderna-set-to-join-sp-500-301335329.html

    SOURCE S&P Dow Jones Indices

    Get the next $SPGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPGI
    $ALXN
    $AZN
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    More analyst ratings

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, S&P Global Mobility Eager William W exercised 254 shares at a strike of $527.79 and covered exercise/tax liability with 115 shares, increasing direct ownership by 2% to 8,863 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/3/26 4:02:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    New insider Joly Hubert claimed ownership of 165 shares (SEC Form 3)

    3 - S&P Global Inc. (0000064040) (Issuer)

    1/9/26 4:02:02 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    SEC Filings

    View All

    SEC Form S-8 filed by AstraZeneca PLC

    S-8 - ASTRAZENECA PLC (0000901832) (Filer)

    2/3/26 3:21:18 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/3/26 7:01:06 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/2/26 1:26:35 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global Introduces New Brand Identity for Mobility Division as "Mobility Global"

    New Brand Reflects the Business as the Global Standard for Automotive Intelligence; Will Be Used Upon Separation as Standalone Public Company NEW YORK, Feb. 3, 2026 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced Mobility Global, Inc ("Mobility Global") will be the corporate name for the S&P Global Mobility business upon completion of its planned separation from S&P Global into a standalone public company. The Mobility Global name reflects its leadership in providing critical intelligence across the vehicle lifecycle to suppliers, OEMs, dealers, and consumers worldwide.

    2/3/26 8:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

    Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo's DATROWAY significantly improved overall survival vs. chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if a

    2/3/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

    Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca's DATROWAY significantly improved overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting Daiichi Sankyo (TSE: 4568) and AstraZeneca's (NYSE:AZN) supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug c

    2/3/26 2:30:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Financials

    Live finance-specific insights

    View All

    S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Dividend Aristocrats Index

    TORONTO, Jan. 23, 2026 /CNW/ - S&P Dow Jones Indices announces the following index changes as a result of the annual S&P/TSX Canadian Dividend Aristocrats Index review. These changes will be effective prior to the open of trading on Monday, February 2, 2026. S&P/TSX Canadian Dividend Aristocrats Index – February 2, 2026 Symbol COMPANY ADDED CEU CES Energy Solutions Corp. ADDED CVE Cenovus Energy Inc ADDED DOO BRP Inc. ADDED GFL GFL Environmental Inc. ADDED GIL Gildan Activewear Inc A ADDED LNR Linamar Corp ADDED MTL Mullen Group Ltd ADDED MTY MTY Food Group Inc ADDED OR OR Royalties Inc. ADDED RCH Richelieu Hardware Ltd ADDED TPZ Topaz Energy Corp. ADDED WTE Westshore Terminals Investment C

    1/23/26 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Increases Dividend 1.0% to $0.97

    NEW YORK, Jan. 14, 2026 /PRNewswire/ -- The Board of Directors of S&P Global (NYSE:SPGI) today approved a 1.0% increase in the regular quarterly cash dividend on the Company's common stock. The 1.0% increase takes into consideration the expected spin of S&P Global's Mobility division into an independent, public company in 2026. The Company has paid a dividend each year since 1937 and is one of fewer than 30 companies in the S&P 500® that has increased its dividend annually for more than 50 years. The quarterly dividend will increase from $0.96 to $0.97 per share.  The dividend

    1/14/26 4:05:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Mobility 2025 Loyalty Awards Reveal Divergent Paths to Customer Retention; General Motors and Tesla Secure Top Honors

    General Motors recognized for 'Overall Loyalty to Manufacturer' for 11th consecutive yearTesla secures 'Overall Loyalty to Make' after a late-year market shift; also wins for 'Highest Conquest %' and 'Ethnic Loyalty to Make'SOUTHFIELD, Mich., Jan. 14, 2026 /PRNewswire/ -- S&P Global Mobility today announced the winners of its 30th annual Automotive Loyalty Awards, with General Motors and Tesla again earning the two highest awards for customer retention. The winners were celebrated during a ceremony at the Detroit Auto Show on January 14, 2026. General Motors received the 'Over

    1/14/26 10:30:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    4/10/24 2:03:52 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by S&P Global Inc. (Amendment)

    SC 13G/A - S&P Global Inc. (0000064040) (Subject)

    2/13/24 5:13:53 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    2/7/24 8:42:56 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Winmark Set to Join S&P SmallCap 600

    NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Winmark Corp. (NASD: WINA) will replace Guess? Inc. (NYSE:GES) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 26. Authentic Brands Group LLC and the Rolling Stockholders are acquiring Guess? in a deal expected to close soon pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Jan 26, 2026 S&P SmallCap 600 Addition Winmark WINA Consumer Discretionary Jan 26, 2026 S&P SmallCap 600 Deletion Guess? GES Consumer Discretionary ABOUT S&P DOW JONES INDICES S&P Dow Jone

    1/21/26 6:01:00 PM ET
    $GES
    $SPGI
    $WINA
    Apparel
    Consumer Discretionary
    Finance: Consumer Services
    Finance

    StandardAero Set to Join S&P MidCap 400

    NEW YORK, Jan. 16, 2026 /PRNewswire/ -- StandardAero Inc. (NYSE:SARO) will replace Frontier Communications Parent Inc. (NASD: FYBR) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, January 22. S&P 500 & S&P 100 constituent Verizon Communications Inc. (NYSE:VZ) is acquiring Frontier Communications Parent in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Jan 22, 2026 S&P MidCap 400 Addition StandardAero SARO Industrials Jan 22, 2026 S&P MidCap 400 Deletion Frontier Communicati

    1/16/26 6:26:00 PM ET
    $FYBR
    $SARO
    $SPGI
    Telecommunications Equipment
    Telecommunications
    Aerospace
    Industrials